The mouse c-rel protein has an N-terminal regulatory domain and a C-terminal transcriptional transactivation domain - PubMed (original) (raw)
The mouse c-rel protein has an N-terminal regulatory domain and a C-terminal transcriptional transactivation domain
P Bull et al. Mol Cell Biol. 1990 Oct.
Abstract
We have shown that the murine c-rel protein can act as a transcriptional transactivator in both yeast and mammalian cells. Fusion proteins generated by linking rel sequences to the DNA-binding domain of the yeast transcriptional activator GAL4 activate transcription from a reporter gene linked in cis to a GAL4 binding site. The full-length mouse c-rel protein (588 amino acids long) is a poor transactivator; however, the C-terminal portion of the protein between amino acid residues 403 to 568 is a potent transcriptional transactivator. Deletion of the N-terminal half of the c-rel protein augments its transactivation function. We propose that c-rel protein has an N-terminal regulatory domain and a C-terminal transactivation domain which together modulate its function as a transcriptional transactivator.
Similar articles
- Transcriptional activation by the v-myb oncogene and its cellular progenitor, c-myb.
Weston K, Bishop JM. Weston K, et al. Cell. 1989 Jul 14;58(1):85-93. doi: 10.1016/0092-8674(89)90405-4. Cell. 1989. PMID: 2665942 - Mutant envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein.
Epinat JC, Kazandjian D, Harkness DD, Petros S, Dave J, White DW, Gilmore TD. Epinat JC, et al. Oncogene. 2000 Feb 3;19(5):599-607. doi: 10.1038/sj.onc.1203376. Oncogene. 2000. PMID: 10698504 - c-rel activates but v-rel suppresses transcription from kappa B sites.
Inoue J, Kerr LD, Ransone LJ, Bengal E, Hunter T, Verma IM. Inoue J, et al. Proc Natl Acad Sci U S A. 1991 May 1;88(9):3715-9. doi: 10.1073/pnas.88.9.3715. Proc Natl Acad Sci U S A. 1991. PMID: 2023921 Free PMC article. - The inhibitory ankyrin and activator Rel proteins.
Nolan GP, Baltimore D. Nolan GP, et al. Curr Opin Genet Dev. 1992 Apr;2(2):211-20. doi: 10.1016/s0959-437x(05)80276-x. Curr Opin Genet Dev. 1992. PMID: 1386268 Review. - NF-kappa B and Rel: participants in a multiform transcriptional regulatory system.
Grilli M, Chiu JJ, Lenardo MJ. Grilli M, et al. Int Rev Cytol. 1993;143:1-62. doi: 10.1016/s0074-7696(08)61873-2. Int Rev Cytol. 1993. PMID: 8449662 Review. No abstract available.
Cited by
- Rel/NF-κB Transcription Factors Emerged at the Onset of Opisthokonts.
Leger MM, Ros-Rocher N, Najle SR, Ruiz-Trillo I. Leger MM, et al. Genome Biol Evol. 2022 Jan 4;14(1):evab289. doi: 10.1093/gbe/evab289. Genome Biol Evol. 2022. PMID: 34999783 Free PMC article. - Promising personalized therapeutic options for diffuse large B-cell Lymphoma Subtypes with oncogene addictions.
Steinhardt JJ, Gartenhaus RB. Steinhardt JJ, et al. Clin Cancer Res. 2012 Sep 1;18(17):4538-48. doi: 10.1158/1078-0432.CCR-12-0217. Epub 2012 Jun 27. Clin Cancer Res. 2012. PMID: 22745106 Free PMC article. Review. - IKK biology.
Liu F, Xia Y, Parker AS, Verma IM. Liu F, et al. Immunol Rev. 2012 Mar;246(1):239-53. doi: 10.1111/j.1600-065X.2012.01107.x. Immunol Rev. 2012. PMID: 22435559 Free PMC article. Review. - In vivo binding of NF-kappaB to the IkappaBbeta promoter is insufficient for transcriptional activation.
Griffin BD, Moynagh PN. Griffin BD, et al. Biochem J. 2006 Nov 15;400(1):115-25. doi: 10.1042/BJ20060786. Biochem J. 2006. PMID: 16792530 Free PMC article.
References
- Nature. 1988 Aug 18;334(6183):629-31 - PubMed
- Proc Natl Acad Sci U S A. 1990 Jun;87(11):4320-4 - PubMed
- Nature. 1988 Oct 6;335(6190):563-4 - PubMed
- Cell. 1988 Nov 4;55(3):395-7 - PubMed
- J Virol. 1988 Dec;62(12):4730-6 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases